| Literature DB >> 32317456 |
Vivek Pravin Dave1, Avinash Pathengay2, Bhavik Panchal2, Animesh Jindal2, Agniv Datta1, Savitri Sharma3, Rajeev Reddy Pappuru1, Joveeta Joseph3, Subhadra Jalali1, Taraprasad Das2.
Abstract
Purpose: To report the clinical presentation, microbiology, and management outcome of endogenous endophthalmitis in Indian patients.Entities:
Keywords: Endogenous; endophthalmitis; outcomes
Mesh:
Substances:
Year: 2020 PMID: 32317456 PMCID: PMC7350439 DOI: 10.4103/ijo.IJO_1091_19
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
Demographic and clinical features of the cases in this series
| Total eyes included | |
|---|---|
| Age | Mean+SD: 25.41±20.46 y; Median: 24 y; Range: 0.1 to 87 y |
| Interval between inciting event and start of symptoms | Mean: 10.12±8.8 d; Median: 4 d; Range: 1 to 24 days |
| Interval between the start of symptoms and presentation to the clinic | Mean+SD: 13.61±30.2 d; Median: 7 d; Range 1-90 d |
| Cases with concurrent corneal infiltrates | |
| Favorable vision at presentation (>20/400) | |
| Favorable vision at last follow up | |
| Anatomic success at last follow up | |
| Mean follow up in months | + SD: Mean 20.35±30.51 m; Median 7 months |
d=Days, m=Months, y=Years
Table showing the various micro -organisms isolated and cultured
| Organism | ||
|---|---|---|
| Gram-positive organism ( | 37 (44.57%) | |
| 9 (10.84%) | ||
| 8 (9.63%) | ||
| 7 (8.43%) | ||
| 6 (7.22%) | ||
| 4 (4.81%) | ||
| 4 (4.81%) | ||
| 3 (3.61%) | ||
| 2 (2.4%) | ||
| 1 (1.2%) | ||
| 1 (1.2%) | ||
| 1 (1.2%) | ||
| Gram negative organisms ( | 15 (23.43%) | |
| 8 (12.5%) | ||
| 7 (10.93%) | ||
| 6 (9.37%) | ||
| 6 (9.37%) | ||
| 5 (7.81%) | ||
| 3 (4.68%) | ||
| 3 (4.68%) | ||
| 2 (3.13%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| 1 (1.56%) | ||
| Fungi ( | 8 (33.33%) | |
| 7 (29.16%) | ||
| 3 (12.5%) | ||
| 2 (8.33%) | ||
| 1 (4.16%) | ||
| 1 (4.16%) | ||
| 1 (4.16%) | ||
| 1 (4.16%) | ||
| Actinomycetes ( | 2 (100%) |
Summary of various systemic foci of infection determined in this series
| Predisposing illness | |
|---|---|
| None | 117 (67.63) |
| Medical conditions | |
| Thrombocytosis | 4 (2.3) |
| HIV | 3 (1.7) |
| Multiorgan failure | 1 (0.6) |
| Liver cirrhosis | 2 (1.2) |
| Typhoid fever | 3 (1.7) |
| Dialysis | 1 (0.6) |
| Urinary tract infection | 2 (1.2) |
| Pyrexia of unknown origin | 18 (10.4) |
| Intravenous fluid injection alone | 7 (4) |
| Cellulitis | 4 (2.4) |
| Surgical conditions | |
| Post solid organ surgery | 5 (2.9) |
| Post-organ transplantation | 2 (1.2) |
| Complicated abortion | 4 (2.4) |
Antimicrobial susceptibilities of various organisms tested
| Antibiotic | Isolates tested | Susceptibility | |
|---|---|---|---|
| Gram-positive organisms ( | Amikacin | 58 | 50% |
| Cefazolin | 68 | 67.64% | |
| Chloramphenicol | 66 | 98.48% | |
| Ciprofloxacin | 59 | 91.52% | |
| Gatifloxacin | 62 | 93.54% | |
| Gentamicin | 22 | 77.27% | |
| Moxifloxacin | 50 | 94% | |
| Ofloxacin | 68 | 94.11% | |
| Vancomycin | 62 | 98.38% | |
| Gram-negative organisms ( | Amikacin | 60 | 60% |
| Ceftazidime | 57 | 54.38% | |
| Chloramphenicol | 64 | 73.43% | |
| Ciprofloxacin | 63 | 79.36% | |
| Gatifloxacin | 61 | 77.04% | |
| Imipenem | 23 | 86.95% | |
| Ofloxacin | 64 | 78.12% | |
| Moxifloxacin | 49 | 73.46% |
Chart 1Summary of management
Comparison of presentations and results of cases with and without underlying systemic illness
| No systemic illness | Underlying systemic illness | 95% C.I. | ||
|---|---|---|---|---|
| Number of eyes | 117 | 56 | ||
| Male gender (%) | 64 (54.7%) | 32 (57.1%) | 0.76 | |
| Mean age (years) | 23.15±19.84 Median 20 | 30.14±24.09 Median 29 | 0.02 | 1-14 |
| Blood culture positivity (%) | 0 | 1 (1.78%) | 0.14 | |
| Urine culture positivity (%) | 3 (2.56%) | 8 (14.28%) | 0.003 | 3.4%-23.29% |
| Vitreous culture positivity (%) | 114 (97.43%) | 47 (83.92%) | 0.001 | 4.75%-25.36% |
| Gram-negative etiology (%) | 33 (28.2%) | 31 (55.35%) | 0.0006 | 11.52%-41.44% |
| Fungal etiology (%) | 11 (9.4%) | 13 (23.21%) | 0.01 | 2.52%-27% |
| Vitrectomy done (%) | 78 (67.2%) | 36 (64.3%) | 0.7 | |
| Favorable functional outcome (%) | 27 (23.07%) | 18 (32.14) | 0.2 | |
| Favorable anatomic outcome (%) | 54 (46.15%) | 22 (39.28%) | 0.39 | |
| Rate of evisceration or enucleation (%) | 2 (1.7%) | 7 (12.5%) | 0.002 | 3.16%-21.99% |
Comparison of features of EE in the current series with previous large literature around the world
| Current series | Muda R | Ratra | Binder | ||||
|---|---|---|---|---|---|---|---|
| 173 | 143 | 61 | 34 | ||||
| Males (%) | 96 (55.5) | 59 (49.2) | 0.26 | 36 (62.1) | 0.37 | 19 (55.5) | 0.98 |
| Mean age (years) | 25.41±20.46 | 52.6±15.1 | <0.0001, −31.24-−23.14 | 34.6±14.9 | 0.002, −14.81-−3.56 | 63.3 | - |
| Identification of primary source of infection (%) | 56 (32.37) | 90 (75) | <0.0001, 32.04%- 51.75% | 31 (53.4) | 0.003, 6.69%- 34.64% | 33 (97) | <0.0001. 50.66%- 71.67% |
| Systemic symptoms identified (%) | 41 (23.7) | 84 (70) | <0.0001 35.79%- 55.27% | 22 (37.9) | 0.03, 1.14%- 27.99% | 23 (67.64) | <0.0001, 25.78%- 58.34% |
| Complaints of blurry vision (%) | 161 (93) | 106 (74) | <0.0001, 10.89%- 27.23% | 60 (98.4) | 0.11 | 31 (92.6) | 0.93 |
| Blood culture positivity (%) | 1 (0.57) | 50 (42) | <0.0001, 33.22%- 49.63% | 2 (5.88) | 0.02, 0.3%- 18.52% | 9 (33.33) | <0.0001, 19.08%- 49.57% |
| Urine culture positivity (%) | 11 (6.35) | 19 (41.3) | <0.0001, 25.91%- 43.6% | 4 (11.6) | 0.88 | 7 (25.9) | 0.001, 5.97%- 38.5% |
| Vitreous culture positivity (%) | 161 (93.06) | 27 (22.3) | <0.0001, 61.79%- 77.42% | 16 (47.05) | <0.0001, 29.11%- 69.88% | 24 (70.58) | 0.0001, 9.01%- 39.49% |
| Gram-negative etiology (%) | 64 (37) | 66 (80.8) | <0.0001, 33.11%- 52.36% | 20 (58.82) | 0.01, 3.64%- 38.13% | 4 (11.76) | 0.004, 8.88%- 35.49% |
| Fungal etiology (%) | 24 (15) | 16 (19.5) | 0.3 | 5 (14.7) | 0.96 | 14 (41.17) | 0.0004, 10.16%- 43.38% |
| Vitrectomy done (%) | 154 (89) | 73 (51.4) | <0.0001, 27.83%- 46.58% | 38 (62.3) | <0.0001, 14.31%- 39.82% | 21 (61.7) | 0.0001, 14.31%- 39.82% |
| Favorable functional outcome (%) | 45 (26.01) | 100 (73) | <0.0001, 28.71%- 48.76% | 18 (29.5) | 0.59 | 12 (35.29) | 0.26 |
| Favorable anatomic outcome (%) | 76 (43.93) | No information | - | 33 (54.09) | 0.17 | ||
| Rate of evisceration or enucleation (%) | 9 (5.2) | 6 (4.19) | 0.67 | 12 (19.7) | 0.0007, 5.33%- 26.39% | 4 (11.76) | 0.15 |